The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout

International Journal of Infectious Diseases

Joanne Daghfal¹  Ali S. Omrani¹  Abdullah Aldushain²  Muna A. Almaslamani²  Mohammed Abukhattab²  Ahmed Zaqout²  Saleh A.N. Hussein²  Israa Alaqad² 

[1] Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar;Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar;

关键词: COVID-19;    SARS-CoV-2;    Coronavirus;    Vaccine;    BNT162b2;    mRNA;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objective: This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar. Methods: All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1–7, 8–14, 15–21, 22–28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period. Results: A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during 15–21, 22–28, and >28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7–93.3% lower during the corresponding time periods (P < 0.001 for each). Conclusion: The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity.

【 授权许可】

Unknown